Many here need, or have needed, to use various eye drops and other treatments, often due directly to thyroid issues. Whether for simple dry eyes or other underlying issues.
Most threads end up with at least one member pointing out the importance of using preservative-free products - especially when they need to be used long-term.
This paper, from Nature and only published about a year ago, identifies that the most widely used preservative, Benzalkonium Chloride, can start causing damage in as little as one week.
(My personal experience was that I went from occasional use of drops to using them more and more frequently as they seemed less effective. Seems pretty obvious that I had gone from being able to tolerate them to needing to avoid. Preservative-free worked for me.)
Very pleased to know of this paper as it backs up what has often been said here. (By me as well as many others.)
• Review Article
• Open Access
• Published: 14 July 2021
Ocular benzalkonium chloride exposure: problems and solutions
• Michael H. Goldstein,
• Fabiana Q. Silva,
• Nysha Blender,
• Trung Tran &
• Srilatha Vantipalli
Eye volume 36, pages 361–368 (2022)
Abstract
Preservatives in multidose formulations of topical ophthalmic medications are crucial for maintaining sterility but can be toxic to the ocular surface. Benzalkonium chloride (BAK)—used in approximately 70% of ophthalmic formulations—is well known to cause cytotoxic damage to conjunctival and corneal epithelial cells, resulting in signs and symptoms of ocular surface disease (OSD) including ocular surface staining, increased tear break-up time, and higher OSD symptom scores. These adverse effects are more problematic with chronic exposure, as in lifetime therapy for glaucoma, but can also manifest after exposure as brief as seven days. Multiple strategies are available to minimize or eliminate BAK exposure, among them alternative preservatives, preservative-free formulations including sustained release drug delivery platforms, and non-pharmacological therapies for common eye diseases and conditions. In this paper, we review the cytotoxic and clinical effects of BAK on the ocular surface and discuss existing and emerging options for ocular disease management that can minimize or eliminate BAK exposure.[/I
Open access available here: